Comparative Pharmacology
Head-to-head clinical analysis: PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE versus VIGAFYDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE versus VIGAFYDE.
PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE vs VIGAFYDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phentermine is a sympathomimetic amine that stimulates norepinephrine release in the hypothalamus, reducing appetite. Topiramate modulates GABA-A receptors, inhibits AMPA/kainate glutamate receptors, and inhibits carbonic anhydrase, enhancing satiety and reducing cravings.
Irreversible inhibitor of GABA transaminase, increasing brain GABA levels.
Oral: Initial 3.75 mg phentermine / 23 mg topiramate once daily for 14 days, then increase to 7.5 mg/46 mg once daily. If <3% weight loss after 12 weeks, discontinue or escalate to 15 mg/92 mg once daily.
Adults: 50 mg/kg/day orally divided twice daily; maximum dose 3 g/day.
None Documented
None Documented
Phentermine: 20-25 hours (terminal); Topiramate: 19-23 hours (healthy adults), prolonged in renal impairment (up to 35 hours). Clinical context: Steady state reached in 4-5 days; supports once-daily dosing.
Terminal elimination half-life is 6-8 hours in adults; in neonates, it is prolonged to 16-20 hours due to immature renal function.
Phentermine: Renal (80% unchanged, 20% as metabolites). Topiramate: Renal (70% unchanged, 30% metabolized). Total dose eliminated renally: >90% combined.
Renal excretion of unchanged drug accounts for approximately 65-70% of elimination; biliary/fecal excretion is minimal (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant